Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antivbody CAMPATH 1-H

Rheumatology

Volumn 42, Issue 12, 2003, Pages 1539-1544

  Lockwood, C M ^c   Hale, G ^a   Waldman, H ^b   Jayne, D R W ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Beh et's disease; CAMPATH 1H; CD52; Lymphocyte depletion; Monoclonal antibody; T cell; Therapy

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; C REACTIVE PROTEIN; CD4 ANTIGEN; CD52 ANTIGEN; CHLORPHENIRAMINE; COLCHICINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HYDROCORTISONE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; PENTOXIFYLLINE; PREDNISOLONE; THALIDOMIDE; THYROXINE;

ADULT; ARTICLE; BEHCET DISEASE; CATARACT; CLINICAL ARTICLE; CLINICAL FEATURE; COLITIS; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HEALTH STATUS; HUMAN; HYPOTHYROIDISM; IMMUNOREACTIVITY; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MALE; MENTAL DISEASE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RELAPSE; REMISSION; SIDE EFFECT; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIRHEUMATIC AGENTS; BEHCET SYNDROME; CD4 LYMPHOCYTE COUNT; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; PREDNISOLONE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 0345099473     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keg424     Document Type: Article

References (26)

1. Sakane T, Takeno M, Suzuki N, Inaba G. Behçet's disease. N Engl J Med 1999;341:1284-91.
2. Kaklamani VG, Vaiopoulos G, Kaklamanis PG. Behçet's disease. Semin Arthritis Rheum 1998;27:197-217.
3. Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease. Lancet 1990;335: 1078-80.
4. Ehrlich GE. Behçet disease and the emergence of thalidomide. Ann Intern Med 1998;128:494-5.
5. Demiroglu H, Ozcebe OI, Barista I, Dundar S, Eldem B. Interferon α-2b, colchicine, and benzathine penicillin versus colchicine and benzathine penicillin in Behçet's disease: a randomised trial. Lancet 2000;355:605-9.
6. Kosar A, Haznedaroglu S, Karaaslan Y et al. Effects of interferon-α2a treatment on serum levels of tumor necrosis factor-α, tumor necrosis factor-α2 receptor, interleukin-2, interleukin-2 receptor, and E-selectin in Behçet's disease. Rheumatol Int 1999;19:11-4.
7. Hirohata S, Suda H, Hashimoto T. Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behçet's disease. J Neurol Sci 1998;159:181-5.
8. Hamuryudan V, Mat C, Saip S et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998;128:443-50.
9. Hamuryudan V, Ozyazgan Y, Hizli N et al. Azathioprine in Behçet syndrome: effects on long-term prognosis. Arthritis Rheum 1997;40:769-74.
10. Calguneri M, Kiraz S, Ertenli I, Benekli M, Karaarslan Y, Celik I. The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behçet's disease. A randomized clinical trial. Arthritis Rheum 1996;39:2062-5.
11. Direskeneli H, Eksioglu-Demiralp E, Kibaroglu A, Yavuz S, Ergun T, Akoglu T. Oligoclonal T cell expansions in patients with Behçet's disease. Clin Exp Immunol 1999;117:166-70.
12. Esin S, Gul A, Hodara V et al. Peripheral blood T cell expansions in patients with Behçet's disease. Clin Exp Immunol 1997;107:520-7.
13. Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease. Lancet 1989;i:1093-6.
14. Bonnet M. Immunosuppressive therapy of Behçet's syndrome. Long term follow-up evaluation. J Fr Ophtalmol 1981;4:455-64.
15. Silingardi V, Montemurno C, Venezia L et al. Clinico-immunological study of 6 cases of Behçet's disease. Minerva Med 1979;70:3269-84.
16. Isaacs JD, Manna VK, Rapson N et al. CAMPATH-1H in rheumatoid arthritis - an intravenous dose-ranging study. Br J Rheumatol 1996;35:231-40.
17. Lockwood CM, Thiru S, Isaacs JD, Hale G, Waldmann H. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet 1993;341:1620-2.
18. Lockwood CM. Refractory Wegener's granulomatosis: a model for shorter immunotherapy of autoimmune diseases. J R Coll Physicians Lond 1998;32:473-8.
19. Paolillo A, Coles AJ, Molyneux PD et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 1999;53:751-7.
20. Dick AD, Meyer P, James T et al. Campath-1H therapy in refractory ocular inflammatory disease. Br J Ophthalmol 2000;84:107-9.
21. Hagen EC, Daha MR, Hermans J et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int 1998; 53:743-53.
22. Zhao MH, Jayne DR, Ardiles LG, Culley F, Hodson ME, Lockwood CM. Autoantibodies against bactericidal/permeability-increasing protein in patients with cystic fibrosis. Q J Med 1996;89:259-65.
23. Wing MG, Moreau T, Greenwood J et al. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcγRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest 1996;98:2819-26.
24. Lockwood CM, Elliott JD, Brettman L et al. Anti-adhesion molecule therapy as an interventional strategy for autoimmune inflammation. Clin Immunol 1999;93: 93-106.
25. Kural-Seyahi E, Fresko I, Seyahi N et al. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003;106:60-76.
26. Coles AJ, Wing M, Smith S et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999;354:1691-5.